Drug-Coated Balloon in Patients With High Bleeding Risk

NCT05221931 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1359

Last updated 2026-02-12

No results posted yet for this study

Summary

DCB-HBR trial is prospective, multi-center, open-label, randomized controlled, noninferiority trial.

The aim of the study is to compare clinical outcomes of drug-coated balloon (DCB) with drug-eluting stent (DES) for treatment of de-novo coronary lesion in patients with high bleeding risk (HBR).

Conditions

Interventions

PROCEDURE

Percutaneous coronary intervention

1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent \[Boston Scientific, USA\], Prevail \[Medtronic, USA\], or SeQuent Please, SeQuent Please NEO \[B-Braun, Germany\])

Sponsors & Collaborators

  • Seoul St. Mary's Hospital

    collaborator OTHER
  • Seoul National University Bundang Hospital

    collaborator OTHER
  • Korea University Ansan Hospital

    collaborator OTHER
  • Chonnam National University Hospital

    collaborator OTHER
  • Chung-Ang University Gwangmyeong Hospital

    collaborator OTHER
  • Gangneung Asan Hospital, University of Ulsan College of Medicine

    collaborator UNKNOWN
  • Gyeongsang National University Hospital

    collaborator OTHER
  • Uijeongbu St. Mary Hospital

    collaborator OTHER
  • Keimyung University Dongsan Medical Center

    collaborator OTHER
  • Inha University Hospital

    collaborator OTHER
  • Chungbuk National University

    collaborator OTHER
  • Wonju Severance Christian Hospital

    collaborator OTHER
  • SMG-SNU Boramae Medical Center

    collaborator OTHER
  • Kangbuk Samsung Hospital, Sungkyunkwan University

    collaborator OTHER
  • Ewha Womans University

    collaborator OTHER
  • Korea University Guro Hospital

    collaborator OTHER
  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Joo Myung Lee, MD, PhD · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-29
Primary Completion
2027-11-30
Completion
2028-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05221931 on ClinicalTrials.gov